Mostrar el registro sencillo del ítem
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | Fernández-Huerta, Miguel | |
dc.contributor.author | Navascués, Ana | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Trobajo-Sanmartín, Camino | |
dc.contributor.author | Casado, Itziar | |
dc.contributor.author | Echeverria, Aitziber | |
dc.contributor.author | Ezpeleta, Carmen | |
dc.contributor.author | Castilla Catalán, Jesús | |
dc.date.accessioned | 2023-10-16T09:57:46Z | |
dc.date.available | 2023-10-16T09:57:46Z | |
dc.date.issued | 2023-09-12 | |
dc.identifier.citation | Vaccines (Basel). 2023 Sep 12;11(9):1478. | es_ES |
dc.identifier.issn | 2076-393X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16551 | |
dc.description.abstract | We estimated influenza vaccine effectiveness (IVE) in preventing outpatient and hospitalized cases in the 2022-2023 season. A test-negative design included a representative sample of outpatients and all hospitalized patients with influenza-like illness (ILI) from October 2022 to May 2023 in Navarre, Spain. ILI patients were tested by PCR for influenza virus. Influenza vaccination status was compared between confirmed influenza cases and test-negative controls. Among 3321 ILI patients tested, IVE to prevent influenza cases was 34% (95% confidence interval (CI): 16 to 48) overall, 85% (95%CI: 63 to 94) against influenza B, and 28% (95%CI: 3 to 46) against A(H3N2). Among 558 outpatients, 222 (40%) were confirmed for influenza: 55% A(H3N2), 11% A(H1N1), and 31% B. Overall, IVE to prevent outpatient cases was 48% (95%CI: 8 to 70), 88% (95%CI: 3 to 98) against influenza B, and 50% (95%CI: -4 to 76) against A(H3N2). Of 2763 hospitalized patients, 349 (13%) were positive for influenza: 64% A(H3N2), 17% A(H1N1), and 8% B. IVE to prevent hospitalization was 24% (95%CI: -1 to 42) overall, 82% (95%CI: 49 to 93) against influenza B, and 16% (95%CI: -17 to 40) against A(H3N2). No IVE was observed in preventing influenza A(H1N1). IVE was high to prevent influenza B, moderate against A(H3N2) and null against A(H1N1). A lower proportion of influenza B cases may explain the smaller IVE in hospitalized patients than in outpatients. The null IVE against A(H1N1) was consistent with the observed antigenic drift and supports the new composition of the 2023-2024 influenza vaccine. | es_ES |
dc.description.sponsorship | This study was supported by the I-MOVE Network (Influenza Monitoring Vaccine Effectiveness in Europe) funded by the European Centre for Disease Prevention and Control (VEBIS project) and by the Instituto de Salud Carlos III with the European Regional Development Fund (CP22/00016, INT21/00100 and PI20/01323). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Case-control study | es_ES |
dc.subject | Influenza | es_ES |
dc.subject | Influenza vaccine | es_ES |
dc.subject | Repeated vaccination | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.title | Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022-2023 | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 37766154 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.number | 9 | es_ES |
dc.format.page | 1478 | es_ES |
dc.identifier.doi | 10.3390/vaccines11091478 | es_ES |
dc.contributor.funder | Unión Europea. European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/vaccines11091478 | es_ES |
dc.identifier.journal | Vaccines | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |